← Back to headlines
AbbVie Reports Positive Late-Stage Results for Subcutaneous Skyrizi in Crohn's Disease
AbbVie announced positive late-stage clinical trial results for its subcutaneous Skyrizi treatment in patients with Crohn's disease, indicating potential for a new therapeutic option.
2 Mar, 16:31 — 2 Mar, 16:31
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Quezon City General Hospital Recognized Among Newsweek’s Top Hospitals in the Philippines
just now
NTNU Study Finds No Link Between Tick Bites and Long-Term Illness
18m ago
Medical Expert Highlights Coffee's Role in Weight Loss and Metabolism
19m ago
Nine-month-old baby died in a kindergarten in Banja Luka
21m ago